Illumina's new NovaSeq platform unveiled at The Institute of Cancer Research, London →
Dr Nik Matthews, Genomics Manager in the ICR's Tumour Profiling Unit. Credit: ICR
It feels a bit strange to be using this blog to link to a news post at my current employer, but I'm happy to share the news that the ICR has become the first organisation in the UK to deploy Illumina's NovaSeq platform.
The ICR's Dr Chris Lord, Deputy Director of the Breast Cancer Now Research Centre, had this to say:
One key area we are keen to use the NovaSeq sequencer for is to discover new ways to select the best available treatment for each individual cancer patient’s specific disease.
If we can do this, we should be able to improve how a significant number of patients are treated. With the NovaSeq system, this kind of work is now feasible – this will be a real game-changer for a lot of the work across the ICR.
Read more in the full news article on the ICR website: